Long-term follow-up using a higher target range for lamotrigine monitoring

Therapeutic Drug Monitoring

Volumn 26, Issue 6, 2004, Pages 626-632

  Morris, Raymond G ^a,b   Lee, Michelle Y Y ^a,b   Cleanthous, Xenia ^b   Black, Andrew B ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Lamotrigine; Target concentration; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

AUSTRALIA; CLINICAL TRIAL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG USE; FOLLOW UP; HUMAN; LABORATORY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SIDE EFFECT;

CHI-SQUARE DISTRIBUTION; DRUG MONITORING; FOLLOW-UP STUDIES; HUMANS; QUESTIONNAIRES; TIME FACTORS; TRIAZINES;

EID: 9644262385     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200412000-00007     Document Type: Review

References (15)

1. Brodie MJ. Lamotrigine versus other antiepileptic drugs: A star rating system is born. Epilepsia. 1994;35:S41-S6.
2. Fraser AD. New drugs for the treatment of epilepsy. Clin Biochem. 1996;29:97-110.
3. Johannessen SI, Battino D. Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363.
4. Perucca E. Marketed new antiepileptic drugs: are they better than old-generation agents? Ther Drug Monit. 2002;24:74-80.
5. Chan V, Morris RG, Ilett KF, et al. Population pharmacokinetics of lamotrigine. Ther Drug Monit. 2001;23:630-635.
6. Morris RG, Black AB, Lam E, et al. Lamotrigine and valproic acid in patients with epilepsy: Using a drug interaction to advantage? Ther Drug Monit. 2000;22:656-660.
7. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol. 2000;55:697-705.
8. Eadie MJ. Therapeutic drug monitoring - antiepileptic drugs. Br J Clin Pharmacol. 1998;46:185-193.
9. Morris RG, Black AB, Harris AL, et al. Lamotrigine and therapeutic drug monitoring: Retrospective survey following the introduction of a routine service. Br J Clin Pharmacol. 1998;46:547-551.
10. Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry. 1993;56:448-453.
11. Schapel GJ, Black AB, Lam EL, et al. Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Seizure. 1996;5:51-56.
12. Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect and concentration-toxicity relations with lamotrigine: A prospective study. Epilepsia. 1996;37:534-538.
13. Peterson GM, McLean S, Millingen KS. A randomised trial of strategies to improve patient compliance with anticonvulsant therapy. Epilepsia. 1984;25:412-417.
14. Black AB. Seizure-free with lamotrigine for refractory epilepsy. Epilepsia. 2000;41(Suppl):72.
15. Wong ICK, Mawer GE, Sander JWAS. Adverse event monitoring in lamotrigine patients: A pharmacoepidemiological study in the United Kingdom. Epilepsia. 2001;42:237-244.